NVO•benzinga•
Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed
Summary
Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 7, 2025 by benzinga